230 related articles for article (PubMed ID: 23337762)
1. Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer.
Lee RJ; Smith MR
Cancer J; 2013; 19(1):90-8. PubMed ID: 23337762
[TBL] [Abstract][Full Text] [Related]
2. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE
Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062
[TBL] [Abstract][Full Text] [Related]
3. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
Smith DC; Smith MR; Sweeney C; Elfiky AA; Logothetis C; Corn PG; Vogelzang NJ; Small EJ; Harzstark AL; Gordon MS; Vaishampayan UN; Haas NB; Spira AI; Lara PN; Lin CC; Srinivas S; Sella A; Schöffski P; Scheffold C; Weitzman AL; Hussain M
J Clin Oncol; 2013 Feb; 31(4):412-9. PubMed ID: 23169517
[TBL] [Abstract][Full Text] [Related]
4. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.
Lee RJ; Saylor PJ; Michaelson MD; Rothenberg SM; Smas ME; Miyamoto DT; Gurski CA; Xie W; Maheswaran S; Haber DA; Goldin JG; Smith MR
Clin Cancer Res; 2013 Jun; 19(11):3088-94. PubMed ID: 23553848
[TBL] [Abstract][Full Text] [Related]
5. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
Cabanillas ME; de Souza JA; Geyer S; Wirth LJ; Menefee ME; Liu SV; Shah K; Wright J; Shah MH
J Clin Oncol; 2017 Oct; 35(29):3315-3321. PubMed ID: 28817373
[TBL] [Abstract][Full Text] [Related]
6. [The treatment of castration-resistant prostate cancer].
Petrányi Á
Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
[TBL] [Abstract][Full Text] [Related]
7. Commentary on "Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial." Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, SchoffskiSchöffski P, Scheffold C, Weitzman AL, Hussain M, University of Michigan, Ann Arbor, MI. J Clin Oncol 2013;31(4):412-9. doi: 10.1200/JCO.2012.45.0494. Epub 2012 Nov 19.
Trump DL
Urol Oncol; 2013 Nov; 31(8):1848. PubMed ID: 24210087
[TBL] [Abstract][Full Text] [Related]
8. Current role of cabozantinib in metastatic castration-resistant prostate cancer.
Fay AP; Albiges L; Bellmunt J
Expert Rev Anticancer Ther; 2015 Feb; 15(2):151-6. PubMed ID: 25586337
[TBL] [Abstract][Full Text] [Related]
9. Bone targeted therapies in metastatic castration-resistant prostate cancer.
Rajpar S; Fizazi K
Cancer J; 2013; 19(1):66-70. PubMed ID: 23337759
[TBL] [Abstract][Full Text] [Related]
10. Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer.
Saylor PJ; Mahmood U; Kunawudhi A; Smith MR; Palmer EL; Michaelson MD
J Nucl Med; 2012 Nov; 53(11):1670-5. PubMed ID: 22984218
[TBL] [Abstract][Full Text] [Related]
11. Bone-targeting agents in prostate cancer.
Suzman DL; Boikos SA; Carducci MA
Cancer Metastasis Rev; 2014 Sep; 33(2-3):619-28. PubMed ID: 24398856
[TBL] [Abstract][Full Text] [Related]
12. Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors.
Desai A; Small EJ
Future Oncol; 2019 Jul; 15(20):2337-2348. PubMed ID: 31184937
[TBL] [Abstract][Full Text] [Related]
13. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor.
Grüllich C
Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794
[TBL] [Abstract][Full Text] [Related]
14. The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile.
Fujita H; Miyadera K; Kato M; Fujioka Y; Ochiiwa H; Huang J; Ito K; Aoyagi Y; Takenaka T; Suzuki T; Ito S; Hashimoto A; Suefuji T; Egami K; Kazuno H; Suda Y; Nishio K; Yonekura K
Mol Cancer Ther; 2013 Dec; 12(12):2685-96. PubMed ID: 24140932
[TBL] [Abstract][Full Text] [Related]
15. The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.
Watanabe K; Hirata M; Tominari T; Matsumoto C; Fujita H; Yonekura K; Murphy G; Nagase H; Miyaura C; Inada M
J Biol Chem; 2016 Sep; 291(40):20891-20899. PubMed ID: 27539855
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.
Zhang J; Jiang X; Jiang Y; Guo M; Zhang S; Li J; He J; Liu J; Wang J; Ouyang L
Eur J Med Chem; 2016 Jan; 108():495-504. PubMed ID: 26717201
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.
Spreafico A; Chi KN; Sridhar SS; Smith DC; Carducci MA; Kavsak P; Wong TS; Wang L; Ivy SP; Mukherjee SD; Kollmannsberger CK; Sukhai MA; Takebe N; Kamel-Reid S; Siu LL; Hotte SJ
Invest New Drugs; 2014 Oct; 32(5):1005-16. PubMed ID: 24788563
[TBL] [Abstract][Full Text] [Related]
18. Novel molecular targets for the therapy of castration-resistant prostate cancer.
Agarwal N; Sonpavde G; Sternberg CN
Eur Urol; 2012 May; 61(5):950-60. PubMed ID: 22209376
[TBL] [Abstract][Full Text] [Related]
19. [Cabozantinib: Mechanism of action, efficacy and indications].
Cochin V; Gross-Goupil M; Ravaud A; Godbert Y; Le Moulec S
Bull Cancer; 2017 May; 104(5):393-401. PubMed ID: 28477875
[TBL] [Abstract][Full Text] [Related]
20. Recent developments in treatments targeting castration-resistant prostate cancer bone metastases.
Loriot Y; Massard C; Fizazi K
Ann Oncol; 2012 May; 23(5):1085-1094. PubMed ID: 22267211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
